Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2014-03-10 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive inleder samarbete i syfte att utvärdera notering av dotterbolag i Taiwan
Share Issue/Capital Change Classification · 1% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated 2014-03-10. The core subject is the initiation of a collaboration to evaluate a potential listing (IPO) of a subsidiary in Taiwan. This involves financing activities, capital structure considerations for the parent company, and strategic growth plans. This announcement is not a full financial report (10-K or IR), an earnings release (ER), or a dividend notice (DIV). It directly relates to fundraising, capital structure changes, and financing strategy, which aligns best with the 'Capital/Financing Update' category. Although it is a press release, its specific content points strongly to CAP rather than the general RNS fallback.
2014-03-10 Swedish
NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan
Delisting Announcement Classification · 1% confidence The document is titled "NEWS RELEASE" and dated March 10, 2014. The content discusses a strategic business decision: starting a collaboration to evaluate an Initial Public Offering (IPO) for a subsidiary on the Taiwanese stock exchange. This announcement concerns future financing activities, capital structure planning for growth, and strategic corporate development, rather than reporting historical financial results (like 10-K or ER), providing a full audit (AR), or announcing a dividend (DIV). The most fitting category for an announcement detailing plans for fundraising, financing, or capital structure changes is 'Capital/Financing Update' (CAP). It is not a formal regulatory filing like a 10-K or a simple report announcement (RPA/RNS), but a substantive business update related to capital strategy.
2014-03-10 English
Major Shareholding Notification 2014
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in the issuer (Abliva AB). It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and percentages, noting the 'Reason for major shareholding notification' as 'New share issue'. This structure perfectly matches the definition of a Major Shareholding Notification, which tracks when ownership crosses specific thresholds. The corresponding code is MRQ.
2014-02-25 English
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is a 'Bokslutskommuniké' (Year-end Report) for NeuroVive Pharmaceutical AB, covering the full fiscal year 2013. It contains comprehensive financial statements (income statement, cash flow, financial position), management's discussion and analysis of business trends, operational milestones, and significant events. It is a substantive financial report for a period shorter than a full annual report (or a preliminary year-end report), fitting the definition of an Interim/Quarterly Report (IR). FY 2013
2014-02-19 Swedish
Annual Report 2013
Annual Report Classification · 1% confidence The document is titled 'YEAR-END REPORT' and covers the full fiscal year (1 Jan 2013 – 31 Dec 2013). It contains detailed financial statements, including income statements, cash flow, and balance sheet data, as well as management commentary on business operations and performance. Since it covers a full fiscal year and provides comprehensive financial data, it is classified as an Annual Report (10-K equivalent for this jurisdiction). FY 2013
2014-02-19 English
NeuroVive treats final patient in European phase III trial on CicloMulsion®
Legal Proceedings Report Classification · 1% confidence The document is a 'NEWS RELEASE' dated February 17, 2014, announcing a clinical trial milestone: 'NeuroVive treats final patient in European phase III trial on CicloMulsion®'. It provides a brief update on the status of the trial (enrollment complete, moving to follow-up) and general company information. This format, which is a short press release announcing operational progress rather than detailed financial results (ER), a formal report (10-K, IR), or a specific regulatory event like a dividend or director dealing, fits best under the general category for miscellaneous regulatory announcements or news releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general news release announcing operational progress, especially since it is explicitly stated that the company is 'required to publish the information in this news release under The Swedish Securities Market Act.' It is too brief and focused on operational news to be an Earnings Release (ER) or Management Discussion (MDA).
2014-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.